Inactive Instrument

Highlights Ceapro Inc Toronto S.E.

Equities

CZO

CA1499071076

Highlights

Unlock all the news: Be the first to know and act before the market!

Aeterna and Ceapro Brief: Cos Complete Merger Transaction; New Name Expected to be Announced in Coming Weeks and Details of AGM Expected to be Announced Shortly	06-03	MT
Aeterna Zentaris Inc. completed the acquisition of Ceapro Inc. in a merger of equals transaction.	06-02	CI
Ceapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna Merger	05-29	MT
Ceapro Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-29	CI
Aeterna Zentaris Finalizes Some Details for Ceapro Merger	05-17	MT
Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro	05-17	MT
Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	03-28	MT
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	03-28	MT
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	03-27	MT
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency	03-27	MT
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share	03-27	MT
Ceapro Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR Arrangement Agreement to Approve Merger of Equals to Create a Diversified Biopharmaceutical Co	02-26	MT
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co	12-14	MT
Aeterna Zentaris and Ceapro Brief: Cos Announcing Merger of Equals to Create a Diversified Biopharmaceutical Co	12-14	MT
Ceapro Inc. Announces Dosing of First Patients In Phase 1-2a Study of Avenanthramides	12-13	MT
Ceapro Inc. Announces Commencement of Patient Dosing in its Phase 1-2a Study Evaluating its Product, Avenanthramides, for Potential Applications in Managing Conditions Related to Inflammation	12-13	CI
Ceapro Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-29	CI
Ceapro Inc. Initiates Phase 1-2a Study Assessing Avenanthramides For Potential Applications in Inflammation Based Diseases	11-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ceapro Inc Toronto S.E.

Equities

CZO

CA1499071076

Highlights

Filters